

ANSM's AI-Assisted Pharmacovigilance — France's Machine-Learning Pre-Coding of COVID-19 Vaccine Adverse-Event Reports

AI in the Public Sector · Good practice · France

Quality score: 60/100

Evidence strength: Moderate

Summary

France's ANSM built an AI module to pre-code COVID-19 vaccine adverse-event reports, validated at AUC 0.93 internally and 0.91 on an independent test set, letting ten regional pharmacovigilance centres focus on complex cases during the 2021 surveillance surge.

Key dimensions

Dimension	Score
Evidence of impact / measured public value	2/3
Transparency, fairness & accountability	2/3
Transferability / demonstrated replication	1/3
Scalability beyond pilot	2/3
Governance, capability & sustainability	2/3

Evaluated by C-NAPSE

Data sources

[C-NAPSE web research](#) — accessed 2026-09-28

[Agence nationale de sécurité du médicament et des produits de santé \(ANSM\), with INSERM, Bordeaux University Hospital and Synapse Medicine](#) — accessed 2026-09-28

[ANSM official announcement](#) — accessed 2026-09-28

[Peer-reviewed validation study \(PMC\)](#) — accessed 2026-09-28

[TICpharma: ANSM selects Synapse Medicine AI](#) — accessed 2026-09-28

Cite this — Evidoria. *ANSM's AI-Assisted Pharmacovigilance — France's Machine-Learning Pre-Coding of COVID-19 Vaccine Adverse-Event Reports*. Persistent ID: 820e7ec7-0a43-42fb-9c53-24f81fa17fd2.